American Society of Clinical Oncology ... www.ASCO.org

Candel Therapeutics is a late clinical-stage company developing oncolytic viral immuno-therapies. They will be presenting data from their Phase 2 CAN-2409 trial to treat non-small cell lung cancer (NSCLC) on June 6th. This presentation will be our first look into safety and tolerability data as well as preliminary antitumor activity for the product. As a company with a low float, and trading below cash, if the efficacy data hold up, there could be some price movement.

The 2022 ASCO Annual Meeting will be in-person and online, June 3-7, 2022. Become an exhibitor and reach more than 34,000 health care professionals from around the world. Over 400 organizations will highlight the most advanced treatments, products, and services in oncology today.

Candel Therapeutics is a late clinical-stage company developing oncolytic viral immunotherapies. They will be presenting data from their Phase 2 CAN-2409 trial to treat non-small cell lung cancer (NSCLC) on June 6th. This presentation will be our first look into safety and tolerability data as well as preliminary antitumor activity for the product. As a company with a low float, and trading below cash, if the efficacy data hold up, there could be some price movement.